Neonatal sepsis remains one of the leading causes of morbidity and mortality in neonates worldwide. It is characterized by systemic inflammatory response resulting from bacterial invasion, often complicated by organ dysfunction. Early recognition and timely initiation of antibacterial therapy are critical to reduce the risk of severe outcomes. The choice of antibiotics must consider local bacterial prevalence, resistance patterns, and pharmacokinetic properties in neonates. Despite advances in neonatal intensive care and antibiotic regimens, challenges persist due to multidrug-resistant organisms and the delicate physiological status of newborns. Evaluating the effectiveness of current antibacterial therapy protocols is essential to guide evidence-based clinical practice and improve survival rates.
The primary objective of this study was to evaluate the clinical effectiveness and safety of antibacterial therapy in neonates with confirmed or suspected sepsis. Secondary objectives included identifying factors affecting treatment outcomes, assessing the prevalence of antibiotic-resistant pathogens, and providing recommendations for optimized neonatal sepsis management. The aim of this study is to comprehensively evaluate the effectiveness and safety of antibacterial therapy in the management of neonatal sepsis. This research focuses on examining the clinical outcomes of neonates undergoing antibacterial treatment, with particular attention to recovery rates, duration of therapy, and the incidence of complications associated with different therapeutic approaches. A key aspect of the study is the identification of the microbiological spectrum of pathogens responsible for neonatal sepsis and the assessment of their susceptibility to commonly administered antibiotics. The study also investigates the impact of timely initiation of appropriate antibacterial therapy on morbidity and mortality rates among affected neonates. In addition, the research explores the relationship between laboratory indicators, such as complete blood count, C-reactive protein, and procalcitonin levels, and the neonates’ response to antibacterial treatment. By analyzing factors that may contribute to treatment failure or adverse drug reactions, this study seeks to provide evidence-based recommendations for optimizing antibacterial therapy protocols in neonatal intensive care settings. Ultimately, the objective is to enhance clinical decision-making and improve survival rates while minimizing complications and the emergence of antibiotic resistance in this vulnerable patient population.
MATERIALS AND METHODS
A prospective observational study was conducted at the Neonatal Intensive Care Unit of a tertiary care hospital. A total of 120 neonates, aged 0–28 days, with clinically suspected or culture-confirmed sepsis were included. Exclusion criteria were congenital immunodeficiencies and severe congenital anomalies. Blood cultures, complete blood counts, C-reactive protein, and procalcitonin levels were obtained at baseline. Empirical broad-spectrum antibiotics were initiated, followed by culture-guided adjustments. Treatment response was evaluated through clinical parameters, laboratory markers, and duration of hospital stay. Adverse drug reactions were recorded. Statistical analysis involved descriptive statistics, chi-square tests for categorical variables, and logistic regression to identify factors influencing treatment success.
Among the 120 neonates, 85% responded positively to early empirical antibiotic therapy, with survival rates exceeding 90%. Culture-guided adjustments improved pathogen-specific targeting and reduced treatment duration. Gram-negative organisms were identified in 60% of cases, while Gram-positive bacteria accounted for 35%. Multidrug-resistant pathogens were detected in 15% of neonates, requiring combination therapy. Adverse effects were minimal, with only 5% of patients experiencing mild gastrointestinal disturbances. Logistic regression indicated that early therapy initiation within the first six hours of symptom onset was strongly associated with favorable outcomes (p < 0.01).
The study highlights the importance of prompt initiation of antibacterial therapy in neonatal sepsis. Empirical broad-spectrum coverage, followed by culture-directed therapy, is essential to improve survival and reduce complications. Resistance patterns emphasize the need for ongoing surveillance and rational antibiotic use. Individualized treatment based on clinical severity, pathogen type, and neonate-specific pharmacokinetics enhances therapy effectiveness. The findings align with global recommendations and underscore the critical role of multidisciplinary neonatal care in reducing sepsis-related mortality. Limitations include single-center design and a limited sample size, suggesting the need for multicenter studies to validate the findings.
Early and appropriately targeted antibacterial therapy is pivotal in the management of neonatal sepsis. Culture-guided adjustments optimize treatment effectiveness, minimize adverse effects, and improve survival rates. Continuous monitoring of antibiotic resistance and adherence to evidence-based protocols are essential to enhance neonatal outcomes. Future research should focus on innovative therapeutic strategies and rapid diagnostic tools to further improve care for septic neonates.
1. Korang SK, Safi S, Gluud C, et al. Antibiotic regimens for neonatal sepsis – a protocol for a systematic review with meta‑analysis. Syst Rev. 2019;8:306. doi:10.1186/s13643‑019‑1207‑1.
2. Korang SK, Safi S, Nava C, et al. Antibiotic regimens for early‑onset neonatal sepsis. Cochrane Database Syst Rev. 2021;2021(5):CD013837.
3. Soni P, Matoria R, Nagalli M. Antibiotic strategies for neonatal sepsis: navigating efficacy and emerging resistance patterns. Eur J Pediatr. 2025;184(7):439. doi:10.1007/s00431‑025‑06271‑w.
4. Fung PG, Hon EKL, Leung KCA. Antibiotic treatment for neonatal sepsis: changing trends and future directions. Drugs in Context. 2026;2025‑5‑4.
5. Neonatal Sepsis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Available from: NCBI Bookshelf.
6. Evidence review for antibiotics for treating late‑onset neonatal infection (NICE Guideline No. 195). London: National Institute for Health and Care Excellence; 2021.
7. Camacho‑Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. 2013;60(2):367‑389.
8. Bakhuizen SE, de Haan TR, Teune MJ, et al. Meta‑analysis shows that infants who have suffered neonatal sepsis face an increased risk of mortality and severe complications. Acta Paediatr. 2014;103(12):1211‑1218.
9. Escobar GJ, Puopolo KM, Wi S, et al. Stratification of risk of early‑onset sepsis in newborns ≥ 34 weeks’ gestation. Pediatrics. 2014;133(1):30‑36.
10. National Institute for Health and Care Excellence (NICE). Neonatal infection: antibiotics for prevention and treatment. Evidence review H; 2021.